AprilBio Non-Registered Director Heo Byeong-ung Acquires 17,500 Shares via Stock Option Exercise, Minimal Dilution Impact

Non-registered director Heo Byeong-ung of AprilBio exercised stock options on April 13, 2026, acquiring 17,500 common shares at KRW 11,625 per share. This represents only 0.07% of total outstanding shares of approximately 23.41 million, resulting in negligible dilution for existing shareholders.
The stock option exercise is part of long-term incentive compensation for the director and does not involve capital raising for business expansion or debt repayment. Thus, the capital allocation impact is neutral.
[AI Summary]AprilBio's director exercised a small stock option grant, increasing shares by a mere 0.07%, posing no dilution risk and having a neutral share price impact. The counterparty is an insider, keeping governance risk at standard levels.